Abstracts tagged "Fracture risk"

Abstract Number: 2808 • 2018 ACR/ARHP Annual Meeting
T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial
Felicia Cosman¹, E. Michael Lewiecki², Peter R Ebeling³, Eric Hesse⁴, Nicola Napoli⁵, Daria B Crittenden⁶, Maria Rojeski⁶, Wenjing Yang⁶, Cesar Libanati⁷ and Serge Ferrari⁸, ¹Columbia University, New York, NY, ²New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ³Monash University, Melbourne, Australia, ⁴University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁵Campus Bio-Medico University of Rome, Rome, Italy, ⁶Amgen Inc., Thousand Oaks, CA, ⁷UCB Pharma, Brussels, Belgium, ⁸Geneva University Hospital, Geneva, Switzerland
Background/Purpose: BMD is a strong predictor of fracture risk in untreated patients. Recent evidence suggests that BMD achieved during treatment also reflects fracture risk; thus,…
Abstract Number: 1223 • 2017 ACR/ARHP Annual Meeting
Inflammatory Bowel Diseases and the Risks of Fracture and Low Mineral Density: Review of the Literature and Meta-Analysis of Observational Cohorts
Paulina Szafors¹, Thomas Barnetche², Cédric Lukas³, Jacques Morel⁴, Cécile Gaujoux-Viala^5,6, Bernard Combe⁷ and Hélène Che⁸, ¹Department of Rheumatology, Lapeyronie Hospital and University of Montpellier, Montpellier, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ⁵Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁶EA 2415, Montpellier University, Nîmes, France, ⁷Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ⁸Rheumatology, University and Hospital Lapeyronie, University of Montpellier, France
Background/Purpose: Inflammatory bowel diseases (IBD), such as Crohn disease (CD) and ulcerative colitis (UC), are associated with a decreased bone mineral density caused by chronic…
Abstract Number: 1227 • 2017 ACR/ARHP Annual Meeting
Osteoporosis and Breast Cancer: Can FRAX-Based Risk Factors Accurately Predict Further Fractures at This Setting?
Salvador López-Salguero¹, Laura Ranieri², Juan Carlos Ordoñez³, Mariano Andrés^4,5, Jose Ponce⁶ and Isabel Ibero², ¹Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²Reumatología, Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ³RHEUMATOLOGY, Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ⁴Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ⁵Universidad Miguel Hernández, Elche, Spain, ⁶Oncología, Dpt. Oncology, Hospital General Universitario Alicante, Alicante, Spain
Background/Purpose: Women with breast cáncer (BC) are at risk for the development of bone loss and osteoporosis (OP) mainly due to adjuvant therapies, as aromatase…
Abstract Number: 2783 • 2017 ACR/ARHP Annual Meeting
Medications Associated with Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro², Frederick Wolfe² and Kaleb Michaud¹, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Osteoporotic (OP) fractures are a major cause of disability, cost, and mortality in RA. Besides increased OP fracture risk, chronic inflammation and pain predispose…
Abstract Number: 326 • 2017 ACR/ARHP Annual Meeting
Osteoporosis and Vertebral Fractures Are Associated with Disease Activity, Low Vitamin D Levels and Spinal Radiographic Damage in Patients with Axial Spondyloarthritis
Cintia Romera-López¹, Cristina Fernández-Carballido², Miguel Ángel García-Moreno³ and Teresa Pedraz⁴, ¹Rheumatology, Hospital Universitario del Vinalopó, Elche, Spain, ²Hospital General Universitario de Elda, Elda, Spain, ³Hosppital Universitario de Elda, Elda, Spain, ⁴Hospital Universitario de Elda, Elda, Spain
Background/Purpose: Osteoporosis and vertebral fractures are comorbidities of Axial Spondyloarthritis (axSpA). We evaluated the relationship between disease activity and radiographic damage and bone mineral density…
Abstract Number: 328 • 2017 ACR/ARHP Annual Meeting
Secular Trends in the Risk of Fragility Fracture Among Patients with Rheumatoid Arthritis: A General Population-Based Study
Sarah Keller¹, Marcy B. Bolster², Amar Oza³, Sharan K. Rai⁴, Leo Lu³, Yuqing Zhang⁵ and Hyon K. Choi⁴, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The risk of osteoporotic (OP) fracture among patients with rheumatoid arthritis (RA) is higher than that of the general population. The worldwide incidence of…
Abstract Number: 1218 • 2017 ACR/ARHP Annual Meeting
Caffeine Consumption and Risk of Osteoporosis: A Cross Sectional Study of 3, 210 Patients from the National Health and Nutrition Examination Survey
Nicola Berman¹, Teresa Attina², Bruce Cronstein¹, Stephen Honig¹ and Michael Pillinger¹, ¹Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, ²Pediatrics, New York University School of Medicine, New York, NY
Background/Purpose: Adenosine regulates bone metabolism. In vitro studies suggest that direct stimulation of the adenosine A2A receptor increases osteoblasts and diminishes osteoclasts, and thus inhibition…
Abstract Number: 327 • 2016 ACR/ARHP Annual Meeting
Drug Retention Rate of Oral Bisphosphonate in Patients with Rheumatoid Arthritis
Ji-Heh Park¹, Seung-Geun Lee¹, Eun-Kyoung Park², Hee-Sang Tag³ and Geun-Tae Kim⁴, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea, ⁴Kosin University College of Medicine, Busan, South Korea
Background/Purpose: As rheumatoid arthritis (RA) is a well-established risk factor for osteoporosis and compression fracture, non-adherence to bisphosphonate (BP) therapy in patients with RA can…
Abstract Number: 331 • 2016 ACR/ARHP Annual Meeting
Biologic Disease-Modifying Anti-Rheumatic Drug Use and the Risk of Non-Vertebral Osteoporotic Fractures in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study
Takefumi Furuya¹, Eisuke Inoue^1,2, Masanori Nakayama¹, Eiichi Tanaka¹, Katsunori Ikari¹, Ayako Nakajima³, Atsuo Taniguchi¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Center for Clinical Research and Development, National Center for Child Health and Development, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Previous U.S. and Canadian studies [1-3] have suggested that no significant associations exist between use of biologic disease-modifying anti-rheumatic drugs (DMARDs) and risk of…
Abstract Number: 334 • 2016 ACR/ARHP Annual Meeting
Predictors of Fragility Fractures in Patients with Rheumatoid Arthritis Not on Steroids: An Observational Study
Sarah Dyball¹ and Marwan Bukhari², ¹University Hospital South Manchester, Manchester, United Kingdom, ²Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased fracture risk, however, this is confounded by a coexisting use of steroids. This study aims…
Abstract Number: 338 • 2016 ACR/ARHP Annual Meeting
Abaloparatide-SC Significantly Reduces Vertebral and Nonvertebral Fractures and Increases Bone Mineral Density (BMD) Regardless of Age, BMD T-Score, or Prior Fracture at Baseline
F Cosman¹, Gary Hattersley², PD Miller³, Ming-Yu Hu⁴, Luis Augusto Tavares Russo⁵, Bente Riis⁶, Greg Williams⁷ and Lorraine Fitzpatrick⁸, ¹Clinical Research Center, Helen Hayes Hospital, West Haverstraw, NY, ²Research, Radius Health, Inc., Waltham, MA, ³Colorado Center for Bone Research, Lakewood, CO, ⁴Biometrics, Radius Health, Inc., Waltham, MA, ⁵CCBR Brasil, Rua Mena Barreto, 33 Botofogo, 22271, Rio de Janeiro, Brazil, ⁶Nordic Biosciences A/S, 2730 Herlev, Denmark, ⁷Clinical Development, Radius Health, Inc., Waltham, MA, ⁸Chief Medical Officer, Radius Health, Inc., Waltham, MA
Background/Purpose: Abaloparatide is a novel 34 amino acid peptide created to be a potent and selective activator of the PTH 1 receptor signaling pathway and…
Abstract Number: 344 • 2016 ACR/ARHP Annual Meeting
Is Rheumatoid Arthritis a Risk Factor for Fractures: A Systematic Review of Observational Studies
Ambika Gupta¹, Stephanie Pipe², Tanveer Towheed³ and Tassos Anastassiades², ¹Internal Medicine, Queen's University, Kingston, ON, Canada, ²Queen's University, Kingston, ON, Canada, ³Dept of Medicine, Queen's University, Kingston, ON, Canada
Background/Purpose: Rheumatoid Arthritis (RA) is a known risk factor for osteoporosis. There are many factors that contribute to this increased risk, including the use of…
Abstract Number: 355 • 2016 ACR/ARHP Annual Meeting
Fracture Incidence Rates in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis
Raveendhara R. Bannuru¹, Elizaveta Vaysbrot², Mikala Osani², Lenore Buckley³, Howard Fink⁴ and Timothy E. McAlindon⁵, ¹Rheumatology, Tufts Med Ctr, Boston, MA, ²Rheumatology, Tufts Medical Center, Boston, MA, ³Rheumatology, Yale University, North Haven, CT, ⁴Minneapolis VA Health Care System, Washington, DC, ⁵Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Transplants increase risk of bone loss and fractures and reduce quality of life. Information on fracture incidence is important when making clinical decisions about…
Abstract Number: 356 • 2016 ACR/ARHP Annual Meeting
Osteoporotic Fracture As the Main Risk Factor in the Detection of Osteoporosis in Men Under 70 Years
JUAN MARIA BLANCO MADRIGAL^1,2, MARIA LUZ GARCIA VIVAR³, Eva Galindez-Agirregoikoa³, OLAIA BEGOÑA FERNANDEZ BERRIZBEITIA⁴, Itziar Calvo Zorrilla³, Edurne Guerrero Basterretxea³, Esther Ruíz Lucea⁵, Ignacio Torre Salaberri⁶, Lidia Estopiñán-Fortea³, Catalina Gómez Arango⁷ and Amaia Bilbao-González⁸, ¹Rheumatology Department, Basurto University Hospital, VITORIA, Spain, ²Rheumatology, Rheumatology Department, Basurto University Hospital, VITORIA, Spain, ³Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ⁴Rheumatology Department, Basurto University Hospital, BILBAO, Spain, ⁵Rheumatology Department, Basurto University Hospital., Bilbao, Spain, ⁶Rheumatology, Hospital Universitario de Basurto. Bilbao., Bilbao, Spain, ⁷Rheumatology, Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ⁸Research Department, Basurto University Hospital, Bilbao, Spain
Background/Purpose: Osteoporosis (OP) in males under 70 years is less common than postmenopausal and senile, but generates significant social and health costs associated with morbidity…
Abstract Number: 1181 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Incident Fractures in Patients with Systemic Lupus Erythematosus on Dialysis
Brian Le^1,2, Jennifer Waller³, Reshmitha Radhakrishnan⁴, Sun Jung Oh⁴, Monique Bethel^2,5, Christopher Rice⁴ and Laura Carbone^2,6, ¹Department of Internal Medicine, Augusta University, Augusta, GA, ²Specialty Care, Charlie Norwood VA Medical Center, Augusta, GA, ³Biostatistics, Augusta University, Augusta, GA, ⁴School of Medicine, Augusta University, Augusta, GA, ⁵1120 15th Street, BI 5070, Augusta University, Augusta, GA, ⁶Rheumatology, Augusta University, Augusta, GA
Background/Purpose: Osteoporosis and osteoporotic fractures are significant comorbidities in patients with systemic lupus erythematosus (SLE). Hip fractures are being increasingly recognized as a complication of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].